By Hilary Rosselot
Tetra Shares Details about their BPN14770 Trials in Fragile X syndrome
Tetra Therapeutics is officially recruiting 12-45 year old males with Fragile X syndrome for their trials on BPN14770.
Chad Coberly and Francie Kivel from Tetra Therapeutics sat down with the NFXF to share the details you need to know about their current trials, including:
- A brief explanation of the trials
- Eligibility criteria, or what criteria participants need to meet in order to be able to participate in the trial
- Study details, like the number of visits, number of blood draws, and travel reimbursement
- Information about the open label extension, or the trial period for guaranteed access to the study drug upon completion of the initial study
- An estimate of when can we expect to know the results of the trials
Watch this short video to learn more about the Tetra trials:
If you are interested in learning more about the Tetra trials, check out Tetra’s MyFXResearch post.
If you are interested in participating in the trial, complete the contact form at the bottom of the MyFXResearch post to send your information to a nearby site.
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Allos Pharma Inc. Receives FDA Guidance and Support for their Phase 3 Trial of Arbaclofen in Fragile X Syndrome
Allos Pharma Inc. received invaluable FDA feedback on the design of their Phase 3 trial for arbaclofen for the treatment of Fragile X syndrome.
Survey: Developing a Caregiver-Reported Survey in Neurodevelopmental Disorders: The Neurodevelopmental Disorder-Health Index (NDD-HI)
The Center of Health and Technology’s (CheT) Outcomes Division is conducting is conducting a survey to learn about [the most prevalent and impactful symptoms of FXS that the individual experiences, as reported by the caregiver.